Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with rheumatoid arthritis who discontinued and restarted methotrexate had less improvement in disease activity, more side effects, and more initial comorbidities than those who persisted on the therapy.

This review found that common post-acute COVID-19 symptoms include fatigue, dyspnea, insomnia, and anxiety, indicating they can persist beyond 60 days after initial infection.

This study observed that children with multisystem inflammatory syndrome associated with COVID-19 exhibited physical intolerance and fatigue shortly after the acute phase, but significant improvements in exercise capacity, laboratory markers, and cardiac health were reported by six months post-discharge.

In this study, 76% of hospitalized COVID-19 patients experienced post-COVID-19 syndrome with symptoms like difficulty concentrating and fatigue lasting around 150 days, significantly impacting their quality of life through increased pain, discomfort, and anxiety.

This study found that long COVID symptoms vary over time, with pulmonary symptoms improving the most, while hair loss showed the poorest treatment outcomes and several factors like smoking slowed recovery.

This review characterizes breast implant illness and its autoimmune symptoms, reporting an association between breast implants and autoimmune diseases, with explantation relieving symptoms in over half of patients.

This case report documents a 59-year-old woman who developed atypical drug-induced lupus after receiving infliximab for Crohn's disease, with symptoms persisting even after discontinuation.

This meta-analysis estimated that around 80% of patients who had COVID-19 experienced at least one long-term symptom, with fatigue being the most common reported effect.

This scoping review reports that while empirical evidence suggests an overlap between Long/Post Covid-19 syndrome, chronic fatigue syndrome, and fibromyalgia, the underlying molecular mechanisms remain unclear, highlighting the need for standardized definitions and rigorous methodologies in Long Covid research.

This article summarizes current knowledge on treating neurological symptoms of post-COVID-19 syndrome, highlighting the lack of pharmaceutical options and reliance on non-drug therapies to manage symptoms like fatigue, cognitive impairment, and sleep disturbances.

Testosterone therapy can help with androgen deficiency in women but should be used with caution and monitoring due to potential risks.

This commentary discusses the potential use of testosterone therapy for various conditions in women and reports no new clinical results; the authors advocate for more discussion and research in this area.

This study discusses hair loss as a potential late-onset symptom of COVID-19 recovery, with androgenic alopecia and telogen effluvium suggested as possible causes, but provides no new clinical results.

This article discusses a unique case of permanent chemotherapy-induced alopecia in a patient receiving chemotherapy for breast cancer, characterized by a distinctive histologic finding and excludes bone marrow transplantation, but reports no new clinical results.

This review examines medical literature on postfinasteride syndrome and reports no new results; the authors call for more controlled studies on permanent sexual dysfunction and mood changes linked to 5-alpha-reductase inhibitors.

This review discusses post-finasteride syndrome, emphasizing its serious psychological and cognitive symptoms and the need for more research and awareness in the medical community, but provides no new clinical findings.

This case study details a 31-year-old woman diagnosed with secondary syphilis that presented with chronic headaches and hair loss, ultimately attributed to neurosyphilis and alopecia syphilitica.

In this study, researchers found that relying solely on ferritin to assess iron status in young females with higher BMI may lead to inaccurate diagnoses of iron deficiency due to inflammation-related ferritin elevation.

This case report describes a patient with systemic lupus erythematosus whose unusual nephrological presentation led to a diagnosis of C3 glomerulopathy, highlighting the importance of considering atypical findings to broaden diagnostic approaches.

This study suggests that flibanserin may have a similar safety profile in men to that observed in premenopausal women, with positive responses reported for various sexual dysfunctions, but further research is needed.

This case report describes a previously healthy 3-year-old girl who developed scurvy symptoms not directly linked to vitamin C dietary deficiency, highlighting the potential for misdiagnosis in similar cases.

This report describes a rare case of painless thyroiditis induced by prolonged off-label use of Lugol’s solution in a 59-year-old woman.

A balanced diet with key nutrients and possible supplements can help manage post-COVID-19 symptoms.

In this case study, a 26-year-old woman with hypothyroidism experienced significant improvements in energy, emotional balance, and physical discomfort after individualized homeopathic treatment with Kalium carbonium, demonstrating the potential benefits of a holistic approach to care.

This article reviews the unapproved use of testosterone for treating female androgen insufficiency and reports no new clinical results.

This review discusses post-SSRI sexual dysfunction and post-finasteride syndrome, highlighting unknowns about their true incidence and underlying causes, and reports no new clinical results.

This study found that platelet-rich plasma injections for vocal fold scarring and atrophy showed a favorable safety profile and subjective improvements in vocal quality and fatigue over a three-month follow-up.

This study found that post-finasteride syndrome patients showed a tissue-specific methylation pattern of the SRD5A2 promoter in cerebrospinal fluid, potentially affecting neuroactive steroid levels and related behavioral symptoms.

This review discusses various treatments for adult acne in women, including topical, systemic, and alternative therapies, and reports no new clinical results.

In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.